Evolus (NASDAQ:EOLS) Shares Down 5.5% After Insider Selling

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s share price fell 5.5% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $9.31 and last traded at $9.42. 110,433 shares traded hands during trading, a decline of 88% from the average session volume of 938,410 shares. The stock had previously closed at $9.96.

Specifically, insider David Moatazedi sold 16,582 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the transaction, the insider now directly owns 364,927 shares of the company's stock, valued at $3,609,128.03. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Moatazedi sold 111,323 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $10.05, for a total value of $1,118,796.15. Following the completion of the sale, the insider now owns 381,509 shares in the company, valued at $3,834,165.45. The trade was a 22.59% decrease in their position. The disclosure for this sale can be found here.

Analyst Ratings Changes

EOLS has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. BTIG Research started coverage on shares of Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target on the stock. Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Trading Down 6.9%

The firm has a market capitalization of $597.69 million, a P/E ratio of -10.30 and a beta of 1.00. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a 50 day moving average of $10.32 and a 200-day moving average of $11.75.

Hedge Funds Weigh In On Evolus

Hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in Evolus by 9.8% during the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock worth $368,000 after purchasing an additional 2,989 shares during the last quarter. Barclays PLC lifted its holdings in shares of Evolus by 12.9% in the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock worth $1,167,000 after acquiring an additional 12,124 shares during the last quarter. Frontier Capital Management Co. LLC acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $2,648,000. Raymond James Financial Inc. bought a new stake in shares of Evolus during the 4th quarter valued at approximately $575,000. Finally, Comerica Bank acquired a new position in Evolus during the 4th quarter worth approximately $312,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.